News | May 10, 2007

New Data Show Diagnostic Test Reduces Mortality, Costs Associated with BSI

May 11, 2007 - AdvanDx Inc. announced a group of infectious disease specialists, headed by Shmuel Shoham M.D. at the Washington Hospital Center, revealed new clinical data that demonstrated how AdvanDx's PNA FISH diagnostic test reduced mortality and hospital costs associated with staphylococcal bloodstream infections (BSI).

PNA FISH is a rapid, molecular-based test that identifies bacteria and yeast species directly from positive blood cultures. Results are available within hours instead of days, enabling labs to quickly report results to physicians and pharmacists to ensure optimal therapy and reduced death rates for patients afflicted with staphylococcal bloodstream infections. Dr. Shoham presented the data at the 2007 Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. The study occurred at the Washington Hospital Center, which is the largest hospital in the nation's capital and among the 25 largest hospitals in the U.S.

Every year, 350,000 patients acquire bloodstream infections in the U.S., resulting in more than 90,000 deaths and significant costs to the healthcare system. Rapid identification of the causative pathogen ensures early and effective therapy in order to improve patient outcomes. During the study, 202 patients whose blood culture tested positive for Gram-positive cocci (indicating a staphylococcal bloodstream infection) were alternately assigned to a control, or intervention, group. In the intervention group, PNA FISH results and general organism information were relayed to the treating clinician via a call from a hospital liaison, whereas control group patients did not receive a call with PNA FISH results. According to the study, reporting of PNA FISH results led to:

• An 80 percent reduction in intensive care unit (ICU) related mortality due to S. aureus BSIs;
• Median hospital cost savings of $19,441 per patient;
• A 61 percent reduction in patients receiving antibiotics for coagulase-negative staphylococci (CNS), which is often a blood culture contaminant that leads to unnecessary antibiotic therapy even though the patient does not have a true bloodstream infection.

For more information visit

Related Content

CapsoVision Inc. Introduces CapsoCloud for CapsoCam Plus Endoscopy System
Technology | Endoscopes | September 14, 2017
CapsoVision Inc. recently announced the full U.S. launch of CapsoCloud, an exam management system that allows...
Pentax Medical Launches New Slim Linear Ultrasound Endoscope
Technology | Endoscopes | August 17, 2017
Pentax Medical Co. announced the U.S. launch of the Slim Linear Ultrasound Endoscope (EG-3270UK), the company's newest...
Fujifilm Issues Voluntary Recall of All ED-530XT Duodenoscopes
News | Endoscopes | August 03, 2017
August 3, 2017 — On July 21, 2017, Fujifilm issued an Urgent Medical Device Correction and Removal notification infor
Feature | Endoscopes | February 01, 2017 | Ravi Chawat
Several diseases that require the use of endoscopy devices for diagnostics, as well as therapeutics, have been on the
News | Endoscopes | January 16, 2017
January 16, 2017 — Fujifilm Medical Systems has informed the U.S.
Given, Pillcamp, colonoscopy, Angiodysplasias, capsule Endoscopy, LVAD interference

The Given Imaging PillCam Colon system is an example of a capsule endoscopy device the patient swallows to image the gastrointestinal track.

Feature | Endoscopes | January 03, 2017 | Anamika Kumari
The capsule endoscopy systems offer a hands-free and highly accurate imaging modality for healthcare practitioners.
Olympus, Visera 4K UHD System, operative display, endoscopy, ultra-high definition
Technology | Flat Panel Displays | September 15, 2016
Olympus announced that big-screen surgery with 4K UHD (ultra-high definition) endoscopy is now available for ear, nose...
Pentax Medical, Defina endoscope system for Pulmonology, EMEA market
Technology | Endoscopes | July 05, 2016
Pentax Medical announced the launch of a new high-definition (HD) pulmonology endoscopy system in the European, Middle...
Avantis Medical Systems, Third Eye Panoramic colonoscopy device, endoscopes, FDA, resposable

From left to right: (1) Panoramic device’s left-viewing camera, (2) Colonoscope’s forward-viewing camera, (3) Panoramic device’s right-viewing camera. The adenoma seen in this image was hidden from the colonoscope’s view but was detected with the Third Eye Panoramic.

Technology | Colonoscopy Systems | May 23, 2016
Avantis Medical Systems Inc. announced that it has received 510(k) clearance from the U.S. Food & Drug...
Integrated Endoscopy, nuvis single-use arthroscope, AAOS 2016
News | Endoscopes | March 22, 2016
March 22, 2016 — Integrated Endoscopy Inc.
Overlay Init